UBS Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,999,188
| Closed | -$55.6M | – | 10449 |
|
|
2023
Q3 | $55.6M | Buy |
2,999,188
+1,639,717
| +121% | +$18.5M | 0.02% | 780 |
|
|
2023
Q2 | $15M | Buy |
1,359,471
+1,236,323
| +1,004% | +$17.2M | 0.01% | 1672 |
|
|
2023
Q1 | $1.65M | Sell |
123,148
-83,170
| -40% | -$1.44M | ﹤0.01% | 3629 |
|
|
2022
Q4 | $2.55M | Buy |
206,318
+148,293
| +256% | +$2.1M | ﹤0.01% | 3144 |
|
|
2022
Q3 | $809K | Sell |
58,025
-35,265
| -38% | -$568K | ﹤0.01% | 3930 |
|
|
2022
Q2 | $1.29M | Sell |
93,290
-85,190
| -48% | -$1.36M | ﹤0.01% | 3513 |
|
|
2022
Q1 | $2.9M | Buy |
178,480
+36,618
| +26% | +$574K | ﹤0.01% | 3080 |
|
|
2021
Q4 | $2.31M | Sell |
141,862
-119,337
| -46% | -$2.01M | ﹤0.01% | 3598 |
|
|
2021
Q3 | $3.88M | Buy |
261,199
+140,747
| +117% | +$2.25M | ﹤0.01% | 2946 |
|
|
2021
Q2 | $2.41M | Sell |
120,452
-16,548
| -12% | -$328K | ﹤0.01% | 3414 |
|
|
2021
Q1 | $3.16M | Buy |
137,000
+119,961
| +704% | +$3.34M | ﹤0.01% | 3078 |
|
|
2020
Q4 | $421K | Sell |
17,039
-1,641
| -9% | -$54.4K | ﹤0.01% | 4734 |
|
|
2020
Q3 | $775K | Sell |
18,680
-36,794
| -66% | -$1.69M | ﹤0.01% | 3825 |
|
|
2020
Q2 | $2.66M | Sell |
55,474
-1,918
| -3% | -$148K | ﹤0.01% | 2613 |
|
|
2020
Q1 | $3.61M | Sell |
57,392
-14,510
| -20% | -$1.3M | ﹤0.01% | 2217 |
|
|
2019
Q4 | $8.91M | Sell |
71,902
-113,423
| -61% | -$10.2M | ﹤0.01% | 2061 |
|
|
2019
Q3 | $12.3M | Buy |
185,325
+97,505
| +111% | +$6.55M | ﹤0.01% | 1601 |
|
|
2019
Q2 | $6.99M | Buy |
87,820
+35,047
| +66% | +$3.14M | ﹤0.01% | 2053 |
|
|
2019
Q1 | $5.9M | Sell |
52,773
-20,875
| -28% | -$2.28M | ﹤0.01% | 2075 |
|
|
2018
Q4 | $7.42M | Sell |
73,648
-5,253
| -7% | -$544K | ﹤0.01% | 1829 |
|
|
2018
Q3 | $9.97M | Buy |
78,901
+15,776
| +25% | +$1.67M | ﹤0.01% | 1785 |
|
|
2018
Q2 | $5.3M | Sell |
63,125
-143,175
| -69% | -$10.5M | ﹤0.01% | 2299 |
|
|
2018
Q1 | $12.7M | Buy |
206,300
+15,675
| +8% | +$945K | 0.01% | 1497 |
|
|
2017
Q4 | $11.1M | Buy |
190,625
+7,630
| +4% | +$481K | ﹤0.01% | 1631 |
|
|
2017
Q3 | $10.6M | Buy |
182,995
+38,221
| +26% | +$4.12M | ﹤0.01% | 1575 |
|
|
2017
Q2 | $17.5M | Buy |
144,774
+40,680
| +39% | +$4.71M | 0.01% | 1123 |
|
|
2017
Q1 | $11.8M | Sell |
104,094
-30,753
| -23% | -$3.59M | 0.01% | 1366 |
|
|
2016
Q4 | $14.7M | Buy |
134,847
+42,254
| +46% | +$5.03M | 0.01% | 1225 |
|
|
2016
Q3 | $15.2M | Buy |
92,593
+51,270
| +124% | +$8.08M | 0.01% | 1139 |
|
|
2016
Q2 | $5.9M | Buy |
41,323
+31,098
| +304% | +$4.53M | ﹤0.01% | 1802 |
|
|
2016
Q1 | $1.31M | Sell |
10,225
-14,875
| -59% | -$1.76M | ﹤0.01% | 3035 |
|
|
2015
Q4 | $3.75M | Buy |
25,100
+12,550
| +100% | +$2.12M | ﹤0.01% | 2212 |
|
|
2015
Q3 | $2.08M | Sell |
12,550
-5,804
| -32% | -$1.28M | ﹤0.01% | 2703 |
|
|
2015
Q2 | $4.43M | Buy |
18,354
+2,852
| +18% | +$759K | ﹤0.01% | 2200 |
|
|
2015
Q1 | $4.37M | Buy |
15,502
+11,724
| +310% | +$2.54M | ﹤0.01% | 2189 |
|
|
2014
Q4 | $590K | Buy |
+3,778
| New | +$698K | ﹤0.01% | 4045 |
|
UBS Group's ICPT Position: Q4 2023 in Review
UBS Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 2,999,188 shares — an estimated $55.6M sold.
UBS Group first reported a position in ICPT in Q4 2014 and held it in 36 quarters. The position peaked at $55.6M in Q3 2023. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- UBS Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- UBS Group sold 2,999,188 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $55.6M.
- UBS Group first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 36 quarters.
- UBS Group's Intercept Pharmaceuticals, Inc. position peaked at $55.6M in Q3 2023.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.